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Abstract 
Aims: microRNAs (miRNAs) are a class of small noncoding RNAs that can act as key 
modulators in tumorigenesis-related genes. Specifically, it has been suggested that miR-21 
overexpression plays a role in the development and progression of breast cancer. So far, the 
role of miRNAs in pregnancy-associated breast cancer (PABC) has not been investigated.  
Methods and Results: We evaluated miR-21 expression by quantitative RT-PCR in 35 pa-
tients, 25 with PABC and 10 control breast cancer cases not pregnancy-associated with 
similar clinicopathological features. We then analyzed protein expression for PTEN, BCL2 and 
PDCD4 as miR-21 target genes by IHC, and finally correlated the results with patients’ cli-
nicopathological features.  
Significant overexpression of miR-21 in PABC tumors compared to normal adjacent tissue 
was found. Overexpression of miR-21 was frequently found in high grade tumors with loss of 
hormone receptor expression and was significantly associated with positive lymph nodes 
(p=0.025). In PABC patients, PTEN, BCL2 and PDCD4 target protein expression was de-
creased in 80%, 76% and 40% respectively.  
Conclusion: Our study supports the involvement of miR-21 in breast cancer progression and 
metastasis formation in PABC implying a role of this miRNA as a marker for poor prognosis 
in PABC patients. 
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Introduction 
Pregnancy-associated breast cancer (PABC) is 
defined as cancer of the mammary gland diagnosed 
during pregnancy, up to 1 year after delivery or at any 
time while the patient is lactating 1. Although it is a 
relatively infrequent condition with an incidence rate 
of approximately 1-3 cases per 10,000 pregnancies, 
frequently delayed diagnosis leads patients to present 
with large tumors and increased number of positive 
lymph nodes, both elements associated with poor 
survival 2, 3 .  
Recent studies have implicated microRNAs 
(miRNAs) in different types of cancer, acting as key 
modulators of tumorigenesis. miRNAs are small 
fragments of non-coding RNA that are 
post-transcriptionally involved in the regulation of 
gene expression. Since the first miRNA lin 4 was 
identified in Caenorhabditis elegans as being involved 
in development and differentiation processes, more 
than 1,000 miRNAs have been identified in the human 
genome 4. Approximately 3% of genes in the human 
genome encode for miRNAs, and up to 30% of human 
protein-coding genes may be regulated by them 5. 
Furthermore, it was previously demonstrated that in 
breast cancer cells there is a causal link between spe-Journal of Cancer 2011, 2 
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cific miRNAs and alteration of proliferation, migra-
tion and apoptosis, thus contributing to cancer pa-
thogenesis 6, 7 .  
miRNA profiling studies in different solid tu-
mors have shown a cancer type-specific deregulation 
of tumor suppressor genes 8, 9. In particular, miR-21 
has been found to be frequently overexpressed in 
different solid tumors, including breast cancer 10, 11. It 
was demonstrated that miR-21 may affect tumor 
progression through down-regulation of different 
targeted tumor suppressor genes such as phosphatase 
and tensin homolog deleted on chromosome 10 
(PTEN), programmed cell death 4 (PDCD4), B-cell 
lymphoma protein (BCL2), tropomyosin 1 (TPM 1) 
among others 12-14. The potential importance of miR-21 
expression as a marker of poor prognosis in breast 
cancer has been suggested 15, however its role in 
PABC patients has not been investigated.  
 In this study, we analyzed the expression levels 
of miR-21 in a series of PABC cases to evaluate its role 
in the transcriptional regulation of its target genes 
(PTEN, PDCD4 and BCL2) and therefore its impact on 
tumor onset and progression. We then correlated the 
results with clinicopathological data to assess its po-
tential use as prognostic marker in PABC patients. 
Materials and Methods 
Patients  
A total of 35 patients, 25 with PABC and 10 with 
similar clinicopathological features of breast cancer 
but not pregnancy-associated, were obtained from the 
surgical pathology archives of the Laboratory of Pa-
thology, National Cancer Institute, Bethesda, MD, 
USA after IRB approval. Hematoxylin and eosin 
(H&E) stained slides were reviewed to confirm the 
diagnosis and to evaluate their respective histopa-
thological features. Medical records were reviewed 
for relevant clinical data, and hormone receptor ex-
pression data (estrogen receptor (ER), progesterone 
receptor (PR), and Her-2/neu status) in the surgical 
pathology report were added to our database.  
RNA extraction 
Five micron formalin-fixed paraffin-embedded 
(FFPE) tissue sections were deparaffinized, rehy-
drated in graded ethanol and manually needle mi-
crodissected under a microscope to obtain separate 
amounts of tumor and matched normal breast tissue. 
RNA was extracted using the RecoverAllTM Total 
Nucleic Acid Isolation Kit (Applied Biosystems, Fos-
ter City, CA, USA) according to the manufacturer’s 
recommendations. A total of 60 μl of elution solution 
containing low molecular weight RNA (<200 bases) 
was obtained in which concentration and quality of 
the RNA isolated was determined by measuring its 
absorbance using the NanoDropTM 1000 spectropho-
tometer (Thermo Scientific Inc.). RNA final concen-
tration was normalized in all samples. 
miR-21 quantification by real-time PCR 
Real-time PCR analysis of miRNA was per-
formed as previously described 16. A two-step proto-
col requiring reverse transcription with miR-
NA-specific primer, followed by real-time PCR with a 
TaqMan® probe was used. MicroRNA’s quantitative 
assay for miR-21 (assay ID: 000397, Applied Biosys-
tems) was used to evaluate mature miRNA expres-
sion, while RNU6B (assay ID: 001093) was used as 
endogenous control.  
Each RT reaction contained 10 ng of purified low 
molecular weight RNA in a final volume of 20 µl. One 
μl of RT product was used in duplicate for each 
quantitative real time-PCR reaction. Expression data 
were acquired and analyzed in 96-well-plate format 
using an ABI Prism 7000 Sequence Detection System 
(Applied Biosystems). Relative amount of miRNA 
was calculated by comparative threshold cycle (CT) 
method. For normalization of RT-PCR results, RNU6B 
was used as an endogenous control. Changes in ex-
pression levels in tumor samples are shown as relative 
(fold change) to their normal corresponding tissue.  
Immunohistochemistry 
Protein expression of PTEN, PDCD4 and BCL2 
was evaluated by immunohistochemistry using PTEN 
C-term rabbit monoclonal a n t i b o d y  C l o n e :  Y 1 8 4  
(Epitomics, Burlingame, CA, USA); BCL2 mouse 
monoclonal antibody Clone: 124 (Imgenex, San Diego, 
CA, USA) and PDCD4 rabbit monoclonal antibody 
Clone: ab51495 (Abcam, Cambridge, MA, USA). 
Paraffin-embedded sections (5 μm) were depa-
raffinized and rehydrated in graded alcohol. Tissue 
sections were microwaved in 10 mM sodium citrate 
pH 6.0 for 15 minutes and then allowed to cool down. 
Endogenous peroxidase was blocked with 0.3% hy-
drogen peroxide in phosphate buffered saline (PBS) 
for 10 minutes. Sections were then incubated for 1 
hour at room temperature with the BCL2 antibody or 
overnight at 4°C for PDCD4 and PTEN antibodies. For 
negative controls, sections were incubated in parallel 
with their respective matched isotype non-immune 
IgG. After rinsing, the sections were incubated with 
the appropriate secondary antibodies for 30 minutes 
(EnVision+TM Dual Link Kit, Dakocytomation, Car-
pinteria, CA). The staining was visualized with 
3,3'-diaminobenzidine as chromogen and slides were 
counterstained with hematoxylin, dehydrated and 
finally mounted. Human thyroid gland carcinoma Journal of Cancer 2011, 2 
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was used as a positive control for PTEN, whereas 
normal colon tissue was used for the PDCD4 staining. 
For the BCL2 antibody, a lymph node section was 
used as a positive control. 
Level of expression was scored semi- 
quantitatively based on intensity of staining and the 
proportion of tumor cells in the selected section. In-
tensity was recorded as 0 (no staining), 1 (weak 
staining), 2 (moderate staining) or 3 (strong staining), 
and the percentage of stained cytoplasmic/nuclear 
area was recorded. All cases with moderate or strong 
staining in >10 percent of the cells were considered 
positive 17.  
Statistical Analysis 
Results are expressed as the mean values and 
standard error of the mean. Statistical analyses for 
RT-PCR results were performed on ∆CT data. SPSS 
version 13.0 (SPSS, Chicago IL) software was used for 
statistical analysis of data with the unpaired 2-tailed 
Student t-test. P values less than 0.05 were considered 
statistically significant. Survival analysis was per-
formed for overall survival (OS) time, and survival 
curves were constructed according to the Kap-
lan-Meier product-limit method and compared by the 
log-rank test. 
Results 
Clinicopathological data 
There were no significant differences in clinico-
pathogical features between the PABC and control 
groups, as summarized in Table 1.  
Table 1. Clinicopathological characteristics of patients 
with pregnancy-associated breast cancer (PABC) and the 
control group. 
Variable  PABC 
N (%) 
CONTROL
N (%) 
p value
Age in years (Mean)  37 38 0.355
Tumor histology       1.00
 Poorly differentiated  17 (68)   7  (72) 
 Moderately differentiated  8 (32)   3  (28) 
Lymph node metastasis    1.000
 Positive  16 (64) 6  (60) 
 Negative 9  (36) 4  (40) 
Hormone receptors status    0.361
 ER-positive 3  (19) 3  (30) 
 ER-negative   13  (81) 5  (50) 
 PR-positive 6  (38) 3  (30) 1.000
 PR-negative 10  (62) 5  (50) 
 Her-2/neu-positive 1  (06) 3  (30) 0.090
 Her-2/neu-negative 15  (94) 5  (50) 
 
 
The mean age at diagnosis of patients in the 
PABC group was 37 vs. 38 years in the control group 
of patients with not pregnancy-associated breast can-
cer. Age distribution was similar in both groups; more 
than 70% of patients were older than 35 years. All 
tumors were infiltrating ductal carcinomas; 32% were 
moderately differentiated and 68% were poorly dif-
ferentiated tumors, with similar percentage in the 
control group (28% and 72% respectively). Lymph 
node metastasis was present in 64% vs. 60% in the 
control group. In the PABC cases compared with the 
control group, 19% vs. 30% of patients were 
ER-positive, 62% vs. 50% were PR-negative, and 94% 
vs. 50% were HER-2/neu-negative.  
miR-21 expression 
We consistently found overexpression of miR-21 
in the PABC group, and in 80% of the tumor vs. 
matched normal adjacent tissue in the control group 
(Figure 1A-B).  
When the overall level of miR-21 expression was 
compared within the two groups, tumors from PABC 
cases presented a much higher level of expression 
compared to their normal counterparts (average 11.1 
vs. 1.8 fold). We also found higher expression of 
miR-21 in the normal breast tissue of the PABC group 
in comparison with normal breast in the non-PABC 
group (Figure 1C). However, the overall expression of 
miR-21 in the normal breast tissue of PABC cases was 
still lower than in the PABC tumors.  
The median fold-change for all PABC cases was 
5-fold. This value was used then to divide patients 
into two groups: miR-21 moderate expressers (n=11, 
31%) and miR-21 high expressers (n=13, 37%). Since 
all cases showed overexpression of miR-21 compared 
to normal tissue, no low-expressers category was in-
cluded. Tumors with a high overexpression level of 
miR-21 correlated positively with the presence of 
metastatic lymph nodes (p=0.025, Figure 2A). The 
other clinicopathological features of the PABC cases 
did not significantly correlate with miR-21 expression 
levels (Table 2).  
Targeted gene expression 
Protein levels of PTEN, PDCD4 and BCL2 were 
lower in tumors compared with adjacent normal tis-
sue in both groups. PTEN protein expression was 
negative in 80% of PABC cases vs. 70% of the tumors 
in the control group. PDCD4 expression was negative 
in 40% of the PABC cases vs. 20% in the control group. 
For the BCL2 gene, 76% of PABC tumors were nega-
tive vs. 40% of tumors in the control group (Table 3 
and Figure 3). PTEN negative expression was signifi-
cantly correlated with increased miR-21 expression 
(p=0.044). Journal of Cancer 2011, 2 
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Figure 1. miR-21 expression in normal and tumor samples of PABC cases (1A) and the control group (1B). C) Repre-
sentative cases of PABC and non-PABC showing different levels of miR-21 expression. Note the increased levels of miR-21 
expression in normal breast tissue of the PABC group vs. the control group.  
 
 
Survival analysis of the PABC group 
Figure 2B-D summarizes survival analysis. Me-
dian follow-up for the PABC group was 35.5 months. 
No statistically significant difference was observed in 
survival time between the PABC and non-PABC 
groups; however, within cases that overexpressed 
miR-21, a worse prognosis was seen in the group that 
presented with a higher expression level (p=0.990). 
According to tumor histological features and patient 
clinical data, the presence of lymph nodes was the 
only feature that was significantly associated with 
worse patient survival (p=0.174 and p=0.030, respec-
tively). Journal of Cancer 2011, 2 
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Table 2. miR-21 expression levels (moderate/high) of 
tumor vs. normal sample and correlation with the clinico-
pathological features of PABC patients. 
Variable miR-21 expression* p value¶
Moderate  
N (%) 
High 
N (%) 
Age (years)     1.000
 < 35  3 (15) 2  (10) 
 ≥ 35  8 (40) 7  (35) 
Histologic grade†     1.000
 Grade 1  (0)  (0) 
 Grade 2  4 (16) 4  (16) 
 Grade 3  8 (32) 9  (36) 
Lymph node metastasis     0.068
 Positive  6 (26) 10  (44)
 Negative 6  (26) 1  (04) 
ER status    
 Negative 7  (44) 6  (38) 1.000
 Positive  1 (06) 2  (12) 
PR status    
 Negative 5  (31) 5  (31) 1.000
 Positive  3 (19) 3  (19) 
Her-2/ neu status    
 Negative   8 (50) 8  (50) -
 Positive   (0)  (0) 
 
 
 
 
 
 
Table 3. PTEN, BCL2 and PDCD4 protein expression 
analyzed by immunohistochemistry. 
Variable PABC
N (%)
CONTROL 
N (%) 
p value
PTEN  
Positive 5 (20) 3 (30) 0.661
Negative 20 (80) 7 (70) 
BCL2  
Positive 6 (24) 4 (40) 0.420
Negative 19 (76) 6 (60) 
PDCD4  
Positive 15 (60) 8 (80) 0.230
Negative 10 (40) 2 (20) 
 
 
 
 
Figure 2. A) miR-21 expression in PABC samples with metastatic lymph nodes. B-D) Impact of some clinicopathological 
variables on overall survival for PABC patients. Journal of Cancer 2011, 2 
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Figure 3. Immunostaining patterns of PTEN, PDCD4 and BCL2 proteins in representative PABC cases. PTEN is mod-
erately expressed in the normal breast tissue and is weak or negative in most of the tumor cells (A, D, G). Heterogeneous 
PDCD4 expression was observed in PABC tumors, with either weak or moderate staining in different cases (B, E, H). 
Moderate BCL2 expression in the normal breast tissue adjacent to the tumor was found. Variable staining was seen in the 
tumor areas (negative to moderate intensity) (C, F, I).x20. 
 
 
Discussion 
Pregnancy-associated breast cancer is usually 
associated with advanced disease status and poor 
prognosis, although a causal effect of the hormonal 
milieu has not been demonstrated 18. Delayed diag-
nosis due to pregnancy or breastfeeding has been 
suggested as one of the reasons for advanced breast 
cancer in these patients. Recently, in a registry study 
performed in a large Swedish population with breast 
cancer, the 5-year survival rate for PABC was only 
52%, significantly less than the 80% survival rate for 
age-matched patients with a not-recent pregnancy 19. 
Low overall survival in PABC has been associated 
with advanced disease and loss of hormone receptor 
expression  20. Positive regional lymph nodes are 
found more often in PABC patients than in non-PABC 
patients (59%-83% vs. 38%-54%). In our study, PABC 
patients presented similar clinicopathological features 
as in previously published reports, most breast cancer 
samples were poorly differentiated tumors, present-
ing at the time of diagnosis 2 cm or more in size and a 
high rate of positive lymph nodes (64% of the PABC 
cases). A high frequency of negative hormone recep-
tor tumors was also found (ER, PR and Her-2/neu).  
Over the past decades, the published literature 
has demonstrated that gene expression profiling may 
be a useful tool to define the signature of breast cancer Journal of Cancer 2011, 2 
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and predict the prognosis or response to treatment. 
However, similar investigations need to be done to 
evaluate miRNAs that may interfere with such gene 
expression signature. 
A cancer-specific miRNA profile has been inves-
tigated before for breast cancer. Altered expression of 
some genes related with breast cancer tumorigenesis 
and metastasis has been shown to be linked to specific 
miRNAs that may potentially act as tumor suppressor 
or oncogenic miRNAs. Iorio et al. 21 demonstrated the 
existence of a breast cancer-specific signature with 
genome-wide miRNA expression profiling that may 
help to predict prognosis and therapeutic response.  
Overexpression of miR-21 has been consistently 
r e p o r t e d  t o  b e  u p - r e g u l a t e d  i n  m a n y  s o l i d  t u m o r s ,  
including breast cancer, when tumor expression is 
compared with matched normal tissue. Si et al. first 
established a breast cancer c e l l  l i n e  w i t h  m i R - 2 1  
knockdown (MCF-7) and used it in a xenograft model; 
resulting tumors were reduced in size, with low pro-
liferation rate and increased apoptosis in comparison 
with the negative control 22.  
miR-21 has been demonstrated to play a role in 
regulating cell apoptosis through modulating target 
genes as BCL2 and PDCD4 22. Special attention has 
been focused on the anti-apoptotic response of breast 
cancer patients with chemotherapy resistance, where 
miR-21 has been found not only to reduce BCL2 pro-
tein expression but to also activate a whole pathway 
that is related to inhibitors of apoptosis proteins and 
multidrug-resistant proteins 23.  
PTEN has been also suggested to be a miR-21 
target gene. Expression of miR-21 was found nega-
tively correlated with PTEN expression; high expres-
sion of miR-21 was frequently found in the more ag-
gressive breast cancer cases 24. 
Our results are in agreement with previous pub-
lications  15, 24, in that most of the tumors overex-
pressed miR-21. Forty-five percent of the tumor sam-
ples presented with a high level of miR-21 expression 
(more than the median value). This group of cases 
was significantly correlated with positive lymph node 
metastasis (p=0.024), and with poor prognosis.  
miR-21 has been linked with numerous target 
genes (PTEN, TPM1, PDCD4, BCL2 and recently the 
maspin genes), all of them associated with increased 
invasion and metastatic potential in breast cancer 25.  
I n  o u r  s t u d y ,  w h e n  w e  v a l i d a t e d  s o m e  o f  t h e  
targeted genes by immunohistochemistry, a statisti-
cally significant inverse correlation was found only 
between PTEN and miR-21 overexpression. We ob-
served loss of PTEN protein expression in almost 80% 
of the tumors in both groups (PABC vs. control). This 
rate is higher than reported in previous publications 
that have frequently shown loss of PTEN protein ex-
pression in 38- 48% of advanced breast cancer 26, 27. 
The difference in results may be due to the different 
f e a t u r e s  o f  o u r  s t u d y  g r o u p ,  i n  w h i c h  m o s t  o f  t h e  
PABC cases presented with poorly differentiated tu-
m o r s  i n  p a t i e n t s  w i t h  a d v a n c e d  d i s e a s e ,  p o s i t i v e  
lymph node metastasis and negative hormone recep-
tors. Koninki et al. found frequent loss of PTEN ex-
pression in breast tumors that are Her-2 recep-
tor-negative, suggesting that low expression of PTEN 
is one of the co-existent molecular mechanisms that 
lead to resistance to trastuzumab 28, 29.  
The PDCD4 protein has been known as a tumor 
suppressor involved not only in apoptosis but also in 
cell transformation and tumor progression. Recently, 
an inverse correlation between miR-21 and PDCD4 
expression has been proposed 30. In our study we 
found that 40% of the tumors in PABC were PDCD4 
negatively expressed, results that are in agreement 
with previous reports using invasive breast cancer 
cases. 
The BCL2 protein has been proposed as a prog-
nostic marker in breast cancer and it seems to be as-
sociated with ER status, increased dedifferentiation, 
and deregulated proliferation 31. In our study, 76% 
percent of the PABC samples showed loss of BCL2 
protein expression, some of them correlated with 
negative hormone receptor status (of the BCL2 nega-
tive tumors, 89% were also ER-negative, 66% PR- 
negative and 75% Her-2/neu-negative), supporting 
the idea that loss of hormone receptors is associated 
with loss of BCL2 expression.  
Taken together, the results suggest that overex-
pression of miR-21 is involved in many cellular 
processes that are altered in cancer, such as dediffe-
rentiation, proliferation and apoptosis, playing an 
important role in pathogenesis of breast cancer 
through different specific targeted genes. Our study 
supports the association between PTEN and miR-21 in 
PABC. 
Interestingly, we found increase overall expres-
sion level of miR-21 in normal breast tissue of PABC 
in comparison with the control group. It is well 
known that during pregnancy there is an elevated rate 
of proliferation and dedifferentiation of the mammary 
epithelial and myoepithelial cells, stem cells beside 
the pathological alterations of the microenvironment. 
A potential link between tumor and developmental 
biology of the mammary glands during pregnancy 
has been suggested especially in the myoepithelial 
cells of PABC, which exhibit unique alterations in p63 
expression that is suggested represent a biologically 
more aggressive cell population, which could poten-
tially progress to invasive lesions 32. Journal of Cancer 2011, 2 
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This observation suggests that differential 
miRNA expression may occur as a part of the mam-
mary gland histological and physiological reorgani-
zation during pregnancy, lactation or involution that 
may modify gene expression and contribute to tumor 
development or progression. Further studies are 
needed to determine how the miRNA profiles change 
in the mammary gland during pregnancy.  
In conclusion,  our results demonstrate that 
miR-21 is overexpressed in PABC. Changes in the 
expression of target genes such as PTEN,  PDCD4, 
BCL2 support the concept that miR-21 may play an 
important oncogenic role not only in breast cancer but 
also in breast tissue during pregnancy. Expression of 
miR-21 may be a possible indicator of poor prognosis 
in breast cancer for this group of patients.  
 
Acknowledgments 
This research was supported by the Intramural 
Research Program of the NIH, NCI. 
 
Conflict of Interest 
The authors have declared that no conflict of in-
terest exists. 
 
References 
1.  Petrek JA. Breast cancer and pregnancy. Journal of the National 
Cancer Institute; 1994;(16):113-121. 
2.  Ulery M, Carter L, McFarlin BL, Giurgescu C. Pregnan-
cy-associated breast cancer: significance of early detection. 
Journal of midwifery & women's health; 2009;54(5):357-363. 
3. Pentheroudakis  G,  Pavlidis  N. Cancer and pregnancy: poena 
magna, not anymore. Eur J Cancer; 2006;42(2):126-140. 
4.  Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic 
gene lin-4 encodes small RNAs with antisense complementarity 
to lin-14. Cell; 1993;75(5):843-854. 
5.  Sassen S, Miska EA, Caldas C. MicroRNA: implications for 
cancer. Virchows Arch; 2008;452(1):1-10. 
6.  Miska EA. How microRNAs control cell division, differentia-
tion and death. Current opinion in genetics & development; 
2005;15(5):563-568. 
7.  Gaur A, Jewell DA, Liang Y et al. Characterization of micro-
RNA expression levels and their biological correlates in human 
cancer cell lines. Cancer research;2007;67(6):2456-2468. 
8.  Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a 
role in cancer. Nature reviews; 2006;6(4):259-269. 
9.  Lu J, Getz G, Miska EA et al. MicroRNA expression profiles 
classify human cancers. Nature; 2005;435(7043):834-838. 
10. Selcuklu SD, Yakicier MC, Erson AE. An investigation of mi-
croRNAs mapping to breast cancer related genomic gain and 
loss regions. Cancer genetics and cytogenetics; 
2009;189(1):15-23. 
11.  Selcuklu SD, Donoghue MT, Spillane C. miR-21 as a key regu-
lator of oncogenic processes. Biochemical Society transactions; 
2009;37(Pt 4):918-925. 
12. Qi L, Bart J, Tan LP et al. Expression of miR-21 and its targets 
(PTEN, PDCD4, TM1) in flat epithelial atypia of the breast in 
relation to ductal carcinoma in situ and invasive carcinoma. 
BMC cancer; 2009;9:163. 
13.  Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel 
T. MicroRNA-21 regulates expression of the PTEN tumor sup-
pressor gene in human hepatocellular cancer. Gastroenterolo-
gy; 2007;133(2):647-658. 
14. Frankel LB, Christoffersen NR, Jacobsen A, Lindow M, Krogh 
A, Lund AH. Programmed cell death 4 (PDCD4) is an impor-
tant functional target of the microRNA miR-21 in breast cancer 
cells. The Journal of biological chemistry; 2008;283(2):1026-1033. 
15. Yan LX, Huang XF, Shao Q et al. MicroRNA miR-21 overex-
pression in human breast cancer is associated with advanced 
clinical stage, lymph node metastasis and patient poor progno-
sis. RNA (New York, NY); 2008;14(11):2348-2360. 
16. Chen Y, Gelfond JA, McManus LM, Shireman PK. Reproduci-
bility of quantitative RT-PCR array in miRNA expression pro-
filing and comparison with microarray analysis. BMC genom-
ics; 2009;10:407. 
17.  Callagy GM, Pharoah PD, Pinder SE et al. Bcl-2 is a prognostic 
marker in breast cancer independently of the Nottingham 
Prognostic Index. Clin Cancer Res; 2006;12(8):2468-2475. 
18. Kroman N, Mouridsen HT. Prognostic influence of pregnancy 
before, around, and after diagnosis of breast cancer. Breast 
(Edinburgh, Scotland); 2003;12(6):516-521. 
19.  Bladstrom A, Anderson H, Olsson H. Worse survival in breast 
cancer among women with recent childbirth: results from a 
Swedish population-based register study. Clinical breast can-
cer; 2003;4(4):280-285. 
20. Halaska MJ, Pentheroudakis G, Strnad P et al. Presentation, 
management and outcome of 32 patients with pregnan-
cy-associated breast cancer: a matched controlled study. The 
breast journal; 2009;15(5):461-467. 
21. Iorio MV, Casalini P, Tagliabue E, Menard S, Croce CM. Mi-
croRNA profiling as a tool to understand prognosis, therapy 
response and resistance in breast cancer. Eur J Cancer; 
2008;44(18):2753-2759. 
22. Si ML, Zhu S, Wu H, Lu Z, Wu F, Mo YY. miR-21-mediated 
tumor growth. Oncogene; 2007;26(19):2799-2803. 
23.  Bourguignon LY, Xia W, Wong G. Hyaluronan-mediated CD44 
interaction with p300 and SIRT1 regulates beta-catenin signal-
ing and NFkappaB-specific transcription activity leading to 
MDR1 and Bcl-xL gene expression and chemoresistance in 
breast tumor cells. The Journal of biological chemistry; 
2009;284(5):2657-2671. 
24. Huang GL, Zhang XH, Guo GL et al. Clinical significance of 
miR-21 expression in breast cancer: SYBR-Green I-based 
real-time RT-PCR study of invasive ductal carcinoma. Oncolo-
gy reports; 2009;21(3):673-679. 
25. [No authors listed]. The world Health Organization Histologi-
cal Typing of Breast Tumors--Second Edition. The World Or-
ganization. American journal of clinical pathology; 
1982;78(6):806-816. 
26. Tsutsui S, Inoue H, Yasuda K et al. Reduced expression of 
PTEN protein and its prognostic implications in invasive ductal 
carcinoma of the breast. Oncology; 2005;68(4-6):398-404. 
27. Chung MJ, Jung SH, Lee BJ, Kang MJ, Lee DG. Inactivation of 
the PTEN gene protein product is associated with the inva-
siveness and metastasis, but not angiogenesis, of breast cancer. 
Pathology international; 2004;54(1):10-15. 
28. Koninki K, Barok M, Tanner M et al. Multiple molecular me-
chanisms underlying trastuzumab and lapatinib resistance in 
JIMT-1 breast cancer cells. Cancer letters 2010; 294(2):211-219. 
29. Zhang S, Yu D. PI(3)King Apart PTEN's Role in Cancer. Clin 
Cancer Res. 2010;16(17):4325-30 Journal of Cancer 2011, 2 
 
http://www.jcancer.org 
75
30. Lankat-Buttgereit B, Goke R. The tumour suppressor Pdcd4: 
recent advances in the elucidation of function and regulation. 
Biology of the cell; 2009;101(6):309-317. 
31.  Dawson SJ, Makretsov N, Blows FM et al. BCL2 in breast can-
cer: a favourable prognostic marker across molecular subtypes 
and independent of adjuvant therapy received. British journal 
of cancer 2010; 103(5):668-675. 
32. Hsiao YH, Su YA, Tsai HD, Mason JT, Chou MC, Man YG. 
Increased invasiveness and aggressiveness in breast epithelia 
with cytoplasmic p63 expression. International journal of bio-
logical sciences 2010; 6(5):428-442. 